Why the study?
Direct oral anticoagulants are recommended as new standard care for cancer-associated venous thromboembolism, but Asian patients were rarely included in pivotal trials.
Do direct oral anticoagulants improve outcomes in Asian patients with cancer-associated venous thromboembolism?
Meta-Analysis (n=3,534)
Do direct oral anticoagulants improve outcomes in Asian patients with cancer-associated venous thromboembolism?
This review highlights the lack of representation of Asian patients in randomized controlled trials establishing DOACs as the standard of care for cancer-associated VTE.
Answers are grounded in this paper and cite their sources.
May support DOAC use in Asian VTE patients; leaves open benefit in cancer-associated VTE given Asian underrepresentation in trials.
Cancer-associated venous thromboembolism is a serious and potentially life-threating event.In the last few years, results of several randomized control trials were published, and direct oral anticoagulants are recommended as new standard care for this disease, however, Asian patients were rarely included in these trials.This article will highlight the limited evidence for Asian patients with cancer-associated venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
A 2020 study conducted a meta-analysis in Venous thromboembolism (n=3,534). Direct oral anticoagulants vs. Warfarin was evaluated on Major and clinically relevant non-major bleeding events in Asian patients (RR 0.67, 95% CI 0.54-0.82).
Synapse has enriched 10 related papers. Consider them for comparative context: